What question did this study set out to answer?

This analysis aimed to assess early symptomatic improvements in patients with moderately to severely active ulcerative colitis following guselkumab induction therapy.

January 23, 2026Journal of Crohn s and Colitis

OP10Symptomatic improvement with intravenous guselkumab induction therapy is observed early in patients with moderately to severely active Ulcerative Colitis: post-hoc analysis of QUASAR

View Full Paper

Ask AI

Bookmark

This analysis aimed to assess early symptomatic improvements in patients with moderately to severely active ulcerative colitis following guselkumab induction therapy.
Conducted a post-hoc analysis of the QUASAR Phase 3 trial (NCT04033445)
Evaluated change in Mayo stool frequency and rectal bleeding subscores
Compared outcomes between intravenous guselkumab (200 mg) and placebo groups at multiple time points
By Day 6, guselkumab patients showed significant improvements in stool frequency (p=0.041) and rectal bleeding (p=0.034) compared to placebo.
At Day 14, guselkumab patients maintained greater improvement in stool frequency (p=0.005) and rectal bleeding (p<0.001).
More patients receiving guselkumab achieved symptomatic response (29.5% at D6; 41.7% at D14) compared to placebo.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Post-hoc analysis evaluates guselkumab's early symptomatic relief in ulcerative colitis, indicating its clinical importance.

Cite This Study

Dignass et al. (2026) studied this question.

synapsesocial.com/papers/69730f59c8125b09b0d1f1e2 https://doi.org/10.1093/ecco-jcc/jjaf231.010

View Full Paper

Ask AI

Bookmark

OP10Symptomatic improvement with intravenous guselkumab induction therapy is observed early in patients with moderately to severely active Ulcerative Colitis: post-hoc analysis of QUASAR

Key Points

Discussion

Implication

Cite This Study

OP10Symptomatic improvement with intravenous guselkumab induction therapy is observed early in patients with moderately to severely active Ulcerative Colitis: post-hoc analysis of QUASAR

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading